Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
暂无分享,去创建一个
M. Gnant | M. Aapro | J. Body | A. Brufsky | T. Guise | R. Coleman | N. Bundred | A. Lipton | P. Hadji
[1] W. Alexander,et al. American Society of Clinical Oncology , 2020, Definitions.
[2] L. Lix,et al. Mortality rates after incident non-traumatic fractures in older men and women , 2011, Osteoporosis International.
[3] Y. Fujiwara,et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Morgan,et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial , 2010, The Lancet.
[5] Jack Cuzick,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.
[6] P. Neven,et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] K. Saag,et al. Health services utilization after fractures: evidence from Medicare. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.
[8] J. Manson,et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Carducci,et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Badamgarav,et al. Cost of fractures commonly associated with osteoporosis in a managed-care population , 2010, Journal of medical economics.
[11] M. Moasser,et al. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results. , 2010 .
[12] M. Ellis,et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. , 2010, The Lancet. Oncology.
[13] U. Dafni,et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial , 2010, Breast Cancer Research.
[14] R E Coleman,et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer , 2010, British Journal of Cancer.
[15] J. Mackey,et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Trentham-Dietz,et al. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk , 2010, British Journal of Cancer.
[17] P. Hadji,et al. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. , 2010, Critical reviews in oncology/hematology.
[18] U. Albert,et al. Assessment of fracture risk in women with breast cancer using current vs emerging guidelines , 2010, British Journal of Cancer.
[19] G. Rennert,et al. Use of bisphosphonates and risk of postmenopausal breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] E. Perez,et al. The Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The Z-FAST Study 5-Year Final Follow-Up. , 2009 .
[21] G. Lenhart,et al. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. , 2009, Bone.
[22] M. Intorcia,et al. PMS66 GRAND: THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NON-ADHERENCE AND ASSOCIATED RISK OF FRACTURES IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES , 2009 .
[23] J. Forbes,et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] V. Hirsh,et al. 20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma , 2009 .
[25] R. Gelber,et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] P. Dong,et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.
[27] E. Perez,et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC , 2009, Breast Cancer Research and Treatment.
[28] J. Eisman,et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. , 2009, JAMA.
[29] T. Fehm,et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. , 2009 .
[30] P. Neven,et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. , 2009 .
[31] H. Gothe,et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis , 2008, Patient preference and adherence.
[32] F. Schuetz,et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] R. Chlebowski,et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M Kalder,et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] D. Dodwell,et al. Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer , 2008, Clinical Cancer Research.
[36] M. Aapro,et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] S. Perera,et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] D. Felsenberg,et al. Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice , 2008, Clinical interventions in aging.
[39] P. Vestergaard,et al. Effect of Tamoxifen and Aromatase Inhibitors on the Risk of Fractures in Women with Breast Cancer , 2008, Calcified Tissue International.
[40] D. Gold,et al. Compliance and persistence with osteoporosis therapies , 2007, Current rheumatology reports.
[41] H. Sommer,et al. [Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study]. , 2008, Deutsche medizinische Wochenschrift.
[42] P. Vestergaard,et al. Adverse bone effects during pharmacological breast cancer therapy , 2008, Acta oncologica.
[43] P. Delmas,et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. , 2007, Bone.
[44] J. Reginster,et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club , 2007, Osteoporosis International.
[45] H. Li,et al. Meta-analysis of clodronate and breast cancer survival , 2007, British Journal of Cancer.
[46] Jacques P. Brown,et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.
[47] S. Cawthorn,et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.
[48] T. Guise,et al. Bone loss and fracture risk associated with cancer therapy. , 2006, The oncologist.
[49] M. Ettinger,et al. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[50] J. Cuzick,et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. , 2006, The Lancet. Oncology.
[51] P. Hadji,et al. Adhärenz mit täglichen und wöchentlichen oralen Bisphosphonaten in der Osteoporosetherapie , 2006 .
[52] T. Powles,et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] , 2006, Breast Cancer Research.
[53] J. Reginster. Adherence and persistence: impact on outcomes and health care resources. , 2006, Bone.
[54] P. Miller. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction , 2005, Current osteoporosis reports.
[55] N. Sutton,et al. Osteoporosis and you! , 2005, Medicine and health, Rhode Island.
[56] C. Blomqvist,et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients , 2004, Acta oncologica.
[57] J. Cauley,et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] A. Oberg,et al. Fracture Risk After Bilateral Oophorectomy in Elderly Women , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[59] James N Ingle,et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] E. Barrett-Connor,et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. , 2001, JAMA.
[61] C. Blomqvist,et al. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer , 2001, British Journal of Cancer.
[62] Janet E Brown,et al. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer , 2010 .
[63] S. Steinberg,et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] J. Thigpen. Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen , 2010 .
[65] P. Hadji. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. , 2009, Critical reviews in oncology/hematology.
[66] Jack Cuzick,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.
[67] G. Hortobagyi,et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] J. Cuzick,et al. OC11. Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II) , 2008 .
[69] A. Howell,et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. , 2008, Cancer treatment reviews.
[70] R. Bartl,et al. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]. , 2006, Deutsche medizinische Wochenschrift.
[71] P. Delmas,et al. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. , 2003, Bone.